WNTH AB Stock Swiss Exchange
Equities
WNT
SE0003553130
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
05-03 | WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
02-29 | WntResearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 36.89M 395M 50.23M |
---|---|---|---|---|---|
Net income 2022 | -30M -321M -40.85M | Net income 2023 | -32M -342M -43.58M | EV / Sales 2022 | - |
Net cash position 2022 | 9.92M 106M 13.51M | Net cash position 2023 | 26.88M 288M 36.61M | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.24
x | P/E ratio 2023 |
-0.87
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 15.12% |
Managers | Title | Age | Since |
---|---|---|---|
Per Norlén
CEO | Chief Executive Officer | 54 | 01-09 |
Founder | 68 | 07-09-23 | |
Anders Tidfors
DFI | Director of Finance/CFO | - | 20-09-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | 15-06-08 | |
Founder | 68 | 07-09-23 | |
Chairman | 62 | 21-12-31 |
1st Jan change | Capi. | |
---|---|---|
+9.84% | 115B | |
+11.71% | 106B | |
-2.59% | 21.96B | |
-13.15% | 21.87B | |
-5.29% | 19.21B | |
-3.84% | 18.08B | |
-38.57% | 17.71B | |
+7.25% | 14.32B | |
+35.54% | 12.42B |
- Stock Market
- Equities
- WNT Stock
- WNT Stock